Current status of intermittent androgen suppression in the treatment of prostate cancer

Urology

Volumn 52, Issue 3, 1998, Pages 353-359

  Theyer, Gerhard ^a   Hamilton, Gerhard ^a  

^a Wilhelminenspital ^*

Author keywords

[No Author keywords available]

Indexed keywords

CYPROTERONE ACETATE; DIETHYLSTILBESTROL; LEUPRORELIN;

CANCER HORMONE THERAPY; CANCER SURVIVAL; DRUG EFFECT; HORMONE INHIBITION; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANIMALS; HUMANS; MALE; PATIENT SELECTION; PROSTATIC NEOPLASMS;

EID: 0032168442     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00251-9     Document Type: Review

References (41)

1. 1. von Eschenbach A, Ho R, Murphy GP, et al: American Cancer Society guideline for the early detection of prostate cancer: update 1997. CA Cancer J Clin 47: 261-264, 1997.
2. 2. Huggins C, and Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293-297, 1941.
3. 3. Galbraith SM, and Duchesne GM: Androgens and prostate cancer: biology, pathology and hormonal therapy. Eur J Cancer 33: 545-554, 1997.
4. 4. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1997. CA Cancer J Clin 47: 5-27, 1997.
5. 5. Bladou F, Vessella RL, Buhler KR, et al: Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. Int J Cancer 67: 785-790, 1996.
6. 6. Reuter VE: Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 49: 16-22, 1997.
7. 7. Akakura K, Bruchovsky N, Goldenberg SL, et al: Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate-specific antigen. Cancer 71: 2782-2790, 1993.
8. 8. Bruchovsky N, Rennie PS, and Vaan Doom E: Pathological growth in androgen-sensitive tissues resulting from latent actions of steroid hormones. J Toxicol Environ Health 4: 391-408, 1978.
9. 9. Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346: 265-269, 1995.
10. 10. Yagoda A, and Petralyk D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71: 1098-1109, 1993.
11. 11. Raghavan D, Koczwara B, and Javle M: Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Cancer 33: 566-574, 1997.
12. 12. Hannun YA: Apoptosis and the dilemma of cancer chemotherapy. Blood 89: 1845-1853, 1997.
13. 13. Theyer G, and Hamilton G: Role of multidrug resistance in tumors of the genitourinary tract. Urology 44: 942-950, 1994.
14. 14. Gleave ME, Bruchovsky N, Goldenberg SL, et al: Intermittent androgen suppression: rationale and clinical experience, in Schröder FH (Ed): Recent Advances in Prostate Cancer and BPH. New York, Parthenon, 1997, pp 109-120.
15. 15. Noble RL: Hormonal control of growth and progression in tumors of Nb rats and a theory of action. Cancer Res 37: 82-94, 1977.
16. 16. Bruchovsky N, Goldenberg SL, Rennie PS, et al: Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma. Urologe [A] 34: 389-392, 1995.
17. 17. Akakura K, Bruchovsky N, Rennie PS, et al: Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shionogi carcinoma. J Steroid Biochem Mol Biol 59: 501-511, 1996.
18. 18. Rennie PS, Bruchovsky N, Akakura A, et al: Effect of tumor progression on the androgenic regulation of the androgen receptor, TRPM-2 and YPT1 genes in the Shionogi carcinoma. J Steroid Biochem Mol Biol 50: 31-39, 1994.
19. 19. Goldenberg SL, Bruchovsky N, Gleave ME, et al: Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 47: 956-961, 1995.
20. 20. Higano CS, Ellis W, Russel K, et al: Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 48: 800-804, 1996.
21. 21. Sato N, Watabe Y, Suzuki H, et al: Progression of androgen-sensitive mouse tumor (shionogi carcinoma 115) to androgen-insensitive tumor after long-term removal of testosterone. Jpn J Cancer Res 84: 1300-1308, 1993.
22. 22. Rennie PS, Bruchovsky N, Buttyan R, et al: Gene expression during the early phases of regression of the androgen-dependent Shionogi mouse mammary carcinoma. Cancer Res 48: 6309-6312, 1988.
23. 23. Bruchovsky N, Rennie PS, Coldman AJ, et al: Effect of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50: 2275-2282, 1990.
24. 24. Gleave ME, Hsieh JT, Wu H-C, et al: Serum PSA levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 52: 1598-1605, 1992.
25. 25. Russo P, Liguori G, Heston WDW, et al: Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic adenocarcinoma. Cancer Res 47: 5967-5970, 1987.
26. 26. Diamond DA, and Barrack ER: The relationship of androgen receptor levels to androgen responsiveness in the Dunning R3327 rat prostate tumor sublines. J Urol 132: 821-827, 1984.
27. 27. Stoll BA: Palliation by castration or hormone administration, in Stoll BA (Ed): Breast Cancer Management Early and Late. Chicago, Year Book Medical Publishers, 1977.
28. 28. Stoll BA: Intermittent hormone therapy in prostate and breast cancers. Eur J Cancer 31A: 2415-2416, 1995.
29. 29. Oliver RT, Williams G, Paris AM, et al: Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology 49: 79-82, 1997.
30. 30. Klotz LH, Herr HW, Morse MJ, et al: Intermittent endocrine therapy for advanced prostate cancer. Cancer 58: 2546-2550, 1986.
31. 31. Miller JI, Ahmann FR, Drach GW, et al: The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 147: 956-961, 1992.
32. 32. Tunn UW: Clinical results of intermittent endocrine treatment in low-volume prostate cancer patients, in Schröder FH (Ed): Recent Advances in Prostate Cancer and BPH. New York, Parthenon, 1997, pp 121-125.
33. 33. Theyer G, Holub S, Durer A, et al: Measurements of tissue polypeptide-specific antigen in prostate cancer patients under intermittent androgen suppression therapy. Br J Cancer 75: 1515-1518, 1997.
34. 34. Trachtenberg J: Experimental treatment of prostatic cancer by intermittent hormonal therapy. J Urol 137: 785-788, 1987.
35. 35. de Reijke TM: Intermittent androgen deprivation in advanced prostate cancer. Urol Res 25: S63-S66, 1997.
36. 36. Gleave ME, Goldenberg SL, Jones EC, et al: Maximal biochemical and pathological downstaging requires 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy. J Urol 155: 213-219, 1996.
37. 37. Gomelia LG, Raj GV, and Moreno JG: Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. J Urol 158: 326-337, 1997.
38. 38. Woodrum DL, Brawer MK, Partin AW, et al: Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 159: 5-12, 1998.
39. 39. Bruchovsky N, Snoek R, Rennie PS, et al: Control of tumor progression by maintenance of apoptosis. Prostate 6S: 13-21, 1996.
40. 40. Bales GT, Sinner MD, Kim JH, et al: Impact of intermittent androgen deprivation on quality of life (QOL). J Urol 155: 578A, 1996.
41. 41. Seay TM, Blute MC, and Zincke H: Radical prostatectomy and early adjuvant hormonal therapy for pTxN+ adenocarcinoma of the prostate. Urology 50: 833-837, 1997.